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Background: Aim of this study was to compare the recurrence rates of bipolar disorder in patients switching from lithium to valproate and from valproate to lithium and to analyze any correlation between baseline characteristics of the patients and occurrence of mood episodes after the treatment switch. 
Methods: Thirty-three responders to lithium and twenty-four responders to valproate who needed or wished to change treatment were followed-up for 18-months after the switch from lithium to valproate or vice versa. 
Results: After the treatment switch, affective recurrences were observed in 42.4% of lithium-responders and in 16.7% of valproate-responders (χ2=4.267; p=.048). Duration of treatment with previous mood stabilizer was the only variable significantly associated with the occurrence of affective episodes (B=.129; Wald=4.658; p=.031). 
Limitations: It was an open, naturalistic study, the sample size was rather small due to the strict inclusion criteria, and no systematic assessments of compliance to treatments were conducted, with the exception of periodic evaluations of plasma levels of mood stabilizer according to clinical practice. 
Conclusions: Our results suggest that in patients with bipolar disorder the recurrence rate is higher in case of switching from lithium to valproate than vice versa. Second, the risk of recurrence is related to the duration of treatment with previous mood stabilizer. 
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Introduction 

Mood stabilizers are defined as drugs that alleviate the severity and the frequency of manic or depressive episodes in patients with bipolar disorder (BD) and do not worsen any of the course variables of the illness (Bowden et al., 1996). 
For many years, lithium was the only mood stabilizer (MS) in common use, and it remains a first choice in the preventive treatment of BD (Grunze et al., 2013). However, it is known that an estimated 20% to 40% of patients may not respond adequately to lithium (Cipriani et al., 2013). Moreover, there are many safety and tolerability concerns such as cognitive impairment, weight gain, dermatologic reactions, and renal or thyroid dysfunction that can lead to lithium discontinuation (Suppes et al., 1993). Discontinuation of lithium for any reason is associated with a higher risk of recurrences even after many years of clinical stability (Biel et el., 2007; Faedda et al., 1993; Mander and Loudon, 1988) and, in case of rapid discontinuation, recurrences increase sharply soon (Baldessarini et al., 1997). Therefore, while lithium is tapered off, an alternative MS should be started. Among mood stabilizers other than lithium, valproate represents a first-line treatment of BD (Yatham et al., 2013). Despite it is commonly used as monotherapy (Baldessarini et al., 2008), the evidence for its effectiveness compared to lithium remains sparse. In the BALANCE study, both lithium-valproate combination and lithium monotherapy were significantly more effective than divalproex monotherapy in preventing recurrences; furthermore, combination therapy was not significantly more effective than lithium alone (Geddes et al., 2010). Similar findings emerged from an observational cohort study with linkage of nationwide registers of patients with BD in psychiatric hospital settings who were treated with valproate or lithium (Kessing et al., 2011). Taken together these results seem to indicate that lithium is superior to valproate in maintenance treatment of BD. However, there is a lack of data regarding the efficacy of valproate in patients that discontinued maintenance treatment with lithium and the same applies for patients switching from valproate to lithium. To our knowledge, there is only a preliminary report focused on cognitive side effects of lithium, showing seven cases where substitution of lithium with valproate was helpful in reducing motivational or creative deficits attributed to lithium (Stoll et al., 1996). 





The study had a prospective observational design and involved a series of BD patients. They had to be euthymic, either responders to monotherapy with lithium (Li-R) or valproate (Va-R), and requiring change of MS for any reason with the exception of lack of efficacy. 
At study entry, Li-R were prescribed valproate and Va-R were prescribed lithium. Within 4 weeks, serum levels of both valproate and lithium were adjusted in order to comply the therapeutic range (valproate: 50-100 mcg/l; lithium: 0.5-0.8 Mmol/l). Discontinuation of previous MS was as long as possible. Each patient was followed-up for 18 months.
Since the observational design of the study, no attempt was made to influence decisions regarding the study treatments and patients received care as usual. 
The aims of the study as well as study procedures were thoroughly explained to potential participants who gave consent before participation.

Subjects
Study participants were either referred by general practitioners or psychiatrists, or self-referred to the Department of Neuroscience (University of Torino) from January 2012 to May 2014.
Patients fulfilling the following inclusion criteria were asked to participate: 1) age of at least 18 years; 2) main diagnosis of BD type I or II, according to DSM-IV-TR; 3) current treatment with lithium or valproate in monotherapy; 4) current euthymic phase since at least 8 weeks; 5) need or wish to discontinue the current MS treatment, except for lack of efficacy.
Exclusion general criteria included: 1) current or recent (less than two months prior the study entry) hypomanic, manic or depressive episode; 2) main diagnosis other than BD; 3) concomitant severe or unstable neurological or physical diseases; 4) history of non-response or any safety/tolerability concerns to valproate for patients in current treatment with lithium or vice versa.

Assessments and procedures
General socio-demographic and clinical information were collected for each subject by looking at medical reports and by directly interviewing the patients. Initial clinical information included type of BD, age of illness onset, duration of illness, duration of treatment and reason for treatment discontinuation. 
Patients were assessed monthly during the first six months, then every 3 months. In addition, all patients were informed to contact their psychiatrists every time they experienced a worsening of symptoms: in this case, another evaluation was conducted. 
In case of BD recurrence, the following data were collected: type of recurrence, time of recurrence, suicide attempts, need of hospitalization and/or compulsory treatment. 

Statistical analysis
First, we compared demographic and clinical characteristics (including recurrence rate after MS switching) between the two patient groups (Li-R and Va-R) by way of chi-square (χ2) in the case of categorical variables and ANOVA (F) in the case of continuous variables. 
A LogReg analysis was then conducted to assess any relationship between characteristics of the patients – independent variables: sex, age, type of BD, age at onset, duration of illness, previous MS (lithium or valproate), duration of treatment with previous MS, stop motivation, reduction time of previous MS – and presence/absence of a recurrent episode of BD (dependent variable).

Results
Fifty-seven patients were enrolled. Thirty-one were males (54.4%) and the mean age of the sample was 46.82 ± 9.79. There was a slight prevalence of patients with BD type II (n=35, 61.4%). 
Thirty-three patients were Li-R and 24 were Va-R. All baseline demographic and clinical characteristics of the two groups are shown in Table 1. Age at onset of the disorder was respectively 25.42 ± 4.95 years in Li-R and 29.13 ± 5.27 years in Va-R (p=.009). Stop motivations were significantly different between the two groups: adverse events occurred in 87.9% of Li-R and 75.0% of Va-R; desire of current MS discontinuation was encountered in 12.1% of Li-R and 4.2% of Va-R, while pregnancy planning in 0% of Li-R and 20.8% of Va-R (p=.017). Most common adverse events leading to discontinuation of MS treatment were tremor (30%), renal dysfunction (15%) and hypothyroidism (9.0%) in Li-R, while weight gain (29.2%), elevated liver enzymes (20.8%), hair loss (12.5%) and sexual side effects (12.5%) occurred in Va-R group.
The mean discontinuation time of MS treatment was 5.0 ± 3.3 and 3.6 ± 2.2 months respectively for Li-R and Va-R (F=3.21; p=0.79). 
As depicted in Table 2, during the 18-months follow-up, recurrences were observed in 14 (42.4%) of Li-R, while 4 (16.7%) of Va-R showed a recurrence (χ2=4.267; p=.048).
With regard to characteristics of recurrences, no significant differences were detected between the two groups. 
The LogReg analysis showed that none of baseline characteristics of patients was significantly associated with BD recurrences with the exception of the duration of treatment with previous MS (B=.129; Wald=4.658; p=.031). 

Discussion
It is known that discontinuation of MS (especially lithium) leads to high risk of recurrence in patients with BD. However, there is a lack of data about the rate of recurrence after switching from a MS to another in euthymic patients requiring change of medication because of any reason. 
We selected 57 patients with BD who were responders to lithium (N=33) or valproate (N=24) monotherapy and needed or wished to change MS because of side effects or other reasons. 
The primary aim of this study was to compare the rate of affective recurrences between the two groups. We found higher rate of affective recurrences after the MS switch in Li-R than in Va-R (42.4% vs 16.7%: p=0.048). The slower tapering of lithium allegedly delayed time to recurrence in Li-R (10 months on average) compared to Va-R (6 months on average), although there were no statistically significant differences neither in terms of reduction time of previous MS nor in terms of time to recurrence. Previous study showed that risk of BD recurrence increased up to 70% in the first year following lithium discontinuation, even after many years of clinical stability (Baastrup et al., 1970; Faedda et al., 1993; Klein et al., 1981; Mander and Loudon, 1988; Mander, 1986). Particularly, a study on BD patients with a good response to lithium maintenance of at least 5 years showed that 62% of them had a recurrence in the first year following discontinuation (Yazici et al., 2004). In light of these data we can argue that, in BD patients discontinuing lithium treatment, valproate confers a mild protective effect against recurrences compared with no MS treatment: approximately 40% of recurrences instead of 70%, as found by the above-mentioned studies. On the other hand, switching from valproate to lithium seems useful in terms of risk of recurrences: only 16.7% of patients had a recurrence during the follow-up period. This finding could be explained by the superior efficacy of lithium over valproate in long-term treatment of BD, as stated by the literature on this topic (Geddes et al., 2010; Kessing et al., 2011) and confirmed in a recent study comparing lithium, valproate, olanzapine and quetiapine as maintenance monotherapy for BD (Hayes et al., 2016). 
The majority of recurrences in our study were (hypo)manic episodes. Likewise, other studies found a prevalence of manic episodes after MS discontinuation (Sharma et al., 2014). Although without statistically significant differences, recurrences in Li-R group appeared more severe than those in Va-R group: higher frequency of psychotic symptoms, hospitalizations and compulsory treatments. Also, 15.1% of Li-R attempted suicide after MS switching compared to none of Va-R. This data is consistent with the study of Baldessarini and colleagues showing an increase of suicidal risk in the first year off lithium (Baldessarini et al., 1997).  
The recurrence rates in Li-R and Va-R should be considered in light of two noteworthy differences in baseline characteristics of the two groups: age at onset was lower in the Li-R than in Va-R, and pregnancy planning was one of the reasons for treatment discontinuation only in Va-R group. A lower age at onset of BD has shown to be related to more frequent manic episodes with psychotic symptoms, short duration of euthymic phases, and higher risk of suicide attempts (Azorin et al., 2013). Thus, the higher rate of recurrences in Li-R could depend on a higher severity of BD in this group. However, among baseline characteristics of the patients, no other markers of severity (e.g. type of BD) were significantly different between Li-R and Va-R. With regard to reasons for discontinuation of MS treatment, since valproate should be stopped in women who are planning to become pregnant, this baseline difference between Li-R and Va-R was expected. Furthermore, no women became pregnant during the follow-up period. Thus, the baseline difference in reasons for treatment discontinuation should not be considered as a potential bias.
The secondary aim of the study was to analyze any correlation between baseline characteristics of the patients and occurrence of mood episodes after the treatment switch. The regression analysis did not confirm the correlation between type of MS at study entry (lithium or valproate) and occurrence of new mood episodes after the treatment switch. The only variable significantly associated with BD recurrences was the duration of previous MS treatment: the longer the period of maintenance treatment with MS, the higher the risk of BD recurrences when discontinued. First, this finding should be interpreted considering the longer duration of treatment in Li-R (7.2 years) than in Va-R (5.5 years). Allegedly, this difference could become statistically significant in a further study examining a sample of larger size. Anyhow, the long duration of treatment with mood stabilizers has no protective effects against recurrences once the treatment is replaced for any reason. 
In conclusion, our results suggest that risk of recurrence in BD patients to whom MS is changed after a long period of mood stability is higher in case of switching from lithium to valproate than vice versa. However, this difference appears to be related more to the duration of MS treatment than to the type of drug switching. 
Limitations
Several limitations should be considered: it was an open, naturalistic study, the sample size was rather small due to the strict inclusion criteria, and no systematic assessments of compliance to treatments were conducted, with the exception of periodic evaluations of plasma levels of MS according to the clinical practice. 
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